Todd Harris - 29 Mar 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Chief Executive Officer, Director
Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Issuer symbol
TYRA
Transactions as of
29 Mar 2023
Net transactions value
-$59,820
Form type
4
Filing time
31 Mar 2023, 19:02:07 UTC
Previous filing
28 Mar 2023
Next filing
05 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Options Exercise $3,195 +1,420 +0.08% $2.25* 1,702,696 29 Mar 2023 Direct
transaction TYRA Common Stock Sale $22,981 -1,420 -0.08% $16.18 1,701,276 29 Mar 2023 Direct F1
transaction TYRA Common Stock Options Exercise $5,416 +2,407 +0.14% $2.25* 1,703,683 30 Mar 2023 Direct
transaction TYRA Common Stock Sale $38,552 -2,407 -0.14% $16.02 1,701,276 30 Mar 2023 Direct F1
transaction TYRA Common Stock Options Exercise $1,125 +500 +0.03% $2.25* 1,701,776 31 Mar 2023 Direct
transaction TYRA Common Stock Sale $8,023 -500 -0.03% $16.05 1,701,276 31 Mar 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -1,420 -0.35% $0.000000 402,444 29 Mar 2023 Common Stock 1,420 $2.25 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -2,407 -0.6% $0.000000 400,037 30 Mar 2023 Common Stock 2,407 $2.25 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -500 -0.12% $0.000000 399,537 31 Mar 2023 Common Stock 500 $2.25 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022.
F2 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.